Clinical Trial: Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV: a Randomized Clinical Trial

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644546) titled 'Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV: a Randomized Clinical Trial' on June 08.

Brief Summary: Seasonal influenza causes morbidity in people with impaired immunity, including adults with elder ages and other comorbidities [1]. Standard-dose inactivated influenza vaccines (IIV) may induce lower hemagglutination inhibition (HAI) titers and more rapid waning in these groups. High-dose IIV could generate higher and more durable serological responses, including HAI, B-cell activation and antibody magnitude, which was demonstrated in randomized trials [2,3]. MF59-adjuvanted IIV further enh...